Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA
Journal of Clinical Medicine · 27.10.2023 · 12 (21) · 6792
DOI: 10.3390/jcm12216792 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.10.2023. Verfasst von Mo-Kyung Sin und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Nursing, Seattle University, Seattle, WA 98122, USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institute on Aging of the National Institute of Health.
Abstract (Originalsprache)
Anti-amyloid therapies (AATs), such as anti-amyloid monoclonal antibodies, are emerging treatments for people with early Alzheimer’s disease (AD). AATs target amyloid β plaques in the brain. Amyloid-related imaging abnormalities (ARIA), abnormal signals seen on magnetic resonance imaging (MRI) of the brain in patients with AD, may occur spontaneously but occur more frequently as side effects of AATs. Cerebral amyloid angiopathy (CAA) is a major risk factor for ARIA. Amyloid β plays a key role in the pathogenesis of AD and of CAA. Amyloid β accumulation in the brain parenchyma as plaques is a pathological hallmark of AD, whereas amyloid β accumulation in cerebral vessels leads to CAA. A better understanding of the pathophysiology of ARIA is necessary for early detection of those at highest risk. This could lead to improved risk stratification and the ultimate reduction of symptomatic ARIA. Histopathological confirmation of CAA by brain biopsy or autopsy is the gold standard but is not clinically feasible. MRI is an available in vivo tool for detecting CAA. Cerebrospinal fluid amyloid β level testing and amyloid PET imaging are available but do not offer specificity for CAA vs amyloid plaques in AD. Thus, developing and testing biomarkers as reliable and sensitive screening tools for the presence and severity of CAA is a priority to minimize ARIA complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Nursing, Seattle University, Seattle, WA 98122, USA.
- Irvine Clinical Research, Irvine, CA 92614, USA.
- VA Medical Center, Washington, DC 20242, USA.
- School of Medicine, Indianna University, Indianapolis, IN 46202, USA.
- School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.
ORCID-Profile: Mo-Kyung Sin, Ali Ahmed
Förderung
- NIA NIH HHS
- NIH HHS
- National Institute on Aging of the National Institute of Health
Zitieren
APA
Sin, M. K., Zamrini, E., Ahmed, A., Nho, K., & Hajjar, I. (2023). Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA. Journal of Clinical Medicine, 12(21), 6792. https://doi.org/10.3390/jcm12216792
Vancouver
Sin MK, Zamrini E, Ahmed A, Nho K, Hajjar I. Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA. Journal of Clinical Medicine. 2023;12(21):6792. doi:10.3390/jcm12216792
BibTeX
@article{Sin2023,
author = {Sin, Mo-Kyung and Zamrini, Edward and Ahmed, Ali and Nho, Kwangsik and Hajjar, Ihab},
title = {Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {21},
pages = {6792},
doi = {10.3390/jcm12216792}
}
EUVIMED